Abaloparatide
Also known as Tymlos, BA058
One-dose burn-down
Half-life
1.7 h
Range
1.0 h–1.7 h
Tmax
31 min
Bioavailability
36%
Typical dose
80 mcg
Synthetic analog of PTH-related protein (PTHrP 1-34) for postmenopausal osteoporosis at high fracture risk. Once-daily subcutaneous injection.
Mechanism of action
Selective agonism of the PTH1 receptor's RG conformation drives bone formation with comparatively less resorption than PTH.
Approved drug (Tymlos). Terminal half-life ~1–1.7 h. Lifetime use of bone-anabolic agents is limited — follow prescribing guidance.
Track Abaloparatide for free
Log your doses and PeptideBuddy models Abaloparatide's half-life into a live chart so you always know how much is active — plus reminders, reconstitution and protocol planning.
Start tracking free